Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05571748
Other study ID # G6PD_Diabetes
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date February 2023
Est. completion date June 2023

Study information

Verified date January 2023
Source University of Thessaly
Contact Athanasios Z Jamurtas, PhD
Phone 2431047054
Email ajamurt@pe.uth.gr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to investigate the effects of alpha-lipoic acid supplementation on redox status, physiological and biochemical parameters in diabetic individuals with G6PD deficiency, after acute exercise.


Description:

In a randomized double-blind, crossover design, a total of forty people will participate in the research voluntarily: (a) ten people with G6PD (Mediterranean type) enzyme deficiency), (b) ten people with G6PD (Mediterranean type) enzyme deficiency and a disorder of carbohydrate metabolism (diabetes, prediabetes), (c) ten people with a disorder of carbohydrate metabolism (diabetes mellitus and prediabetes) and, (d) ten people without any health problem (control group). They will be supplemented with either 600 mg of alpha-lipoic acid (experimental condition) or placebo (control condition) every day for 4 weeks, separated by a 4-week washout period. All participants will be randomly assigned to both conditions. Before intervention, all participants will be informed about the study protocol, fill a medical history questionnaire and sign an informed consent form. Moreover, measurements of anthropometric characteristics and physiological parameters, as well as a VO2peak test will be performed. Participants will perform a trial of exercise (70% VO2peak for 45min and 90% till exhaustion) before and after each condition (i.e. a total of 4 trials). Blood samples will be collected before, immediately after and 1 hour after each exercise trial. Moreover, measurements of anthropometric characteristics, physiological and psychological parameters will be performed before and after each condition.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 40
Est. completion date June 2023
Est. primary completion date March 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Individuals with normal G6PD activity - Individuals with G6PD deficiency - Individuals with CHO metabolism disorders (diabetes, prediabetes) - Individuals with G6PD deficiency and CHO metabolism disorders (diabetes, prediabetes) Exclusion Criteria: - Health problems that contraindicate participation to exercise - Should not take any medication that affects the body's antioxidant mechanisms as well as dietary supplements containing antioxidants - Women during lactation or gestation

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Alpha-lipoic acid
A trial of acute exercise before and after 4 weeks of alpha-lipoic acid supplementation.
Other:
Placebo
A trial of acute exercise before and after 4 weeks of placebo supplementation.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
University of Thessaly

References & Publications (1)

Georgakouli K, Deli CK, Zalavras A, Fatouros IG, Kouretas D, Koutedakis Y, Jamurtas AZ. Alpha-lipoic acid supplementation up-regulates antioxidant capacity in adults with G6PD deficiency. Food Chem Toxicol. 2013 Nov;61:69-73. doi: 10.1016/j.fct.2013.01.055. Epub 2013 Feb 14. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Changes in total antioxidant capacity following 4 weeks of supplementation and placebo at rest and following a trial of acute exercise. Index of blood redox status. Spectrophotometric assay for the determination of total antioxidant capacity using DPPH method. Before, immediately after and 1 hour after each trial of exercise, in both conditions (supplement and placebo)
Primary Changes in glutathione following 4 weeks of supplementation and placebo at rest and following a trial of acute exercise. Index of blood redox status. Spectrophotometric assay for the determination of total antioxidant capacity using DTNB method. Before, immediately after and 1 hour after each trial of exercise, in both conditions (supplement and placebo)
Primary Changes in uric acid following 4 weeks of supplementation and placebo at rest and following a trial of acute exercise. Index of blood redox status. Spectrophotometric assay for the determination of total antioxidant capacity using a clinical chemistry analyzer with commercially available kits. Before, immediately after and 1 hour after each trial of exercise, in both conditions (supplement and placebo)
Primary Changes in bilirubin following 4 weeks of supplementation and placebo at rest and following a trial of acute exercise. Index of blood redox status. Spectrophotometric assay for the determination of bilirubin using a clinical chemistry analyzer with commercially available kits. Before, immediately after and 1 hour after each trial of exercise, in both conditions (supplement and placebo)
Primary Changes in lipid peroxidation following 4 weeks of supplementation and placebo at rest and following a trial of acute exercise. Index of blood redox status. Determination of lipid peroxidation using malondialdehyde production assessment. Before, immediately after and 1 hour after each trial of exercise, in both conditions (supplement and placebo)
Primary Changes in protein carbonyls following 4 weeks of supplementation and placebo at rest and following a trial of acute exercise. Index of blood redox status. Spectrophotometric assay for the determination of total antioxidant capacity using DNPH method. Before, immediately after and 1 hour after each trial of exercise, in both conditions (supplement and placebo)
Primary Changes in blood lipids following 4 weeks of supplementation and placebo at rest and following a trial of acute exercise. Blood lipids (total cholesterol, LDL-c, HDH-c, triglycerides). Spectrophotometric assays for the determination of blood lipids using a clinical chemistry analyzer with commercially available kits. Before, immediately after and 1 hour after each trial of exercise, in both conditions (supplement and placebo)
Primary Changes in insulin resistance following 4 weeks of supplementation and placebo. Measurement of blood glucose and insulin levels to assess HOMA-IR and evaluate insulin resistance. Spectrophotometric assay for the determination of blood glucose using a clinical chemistry analyzer with commercially available kits.Determination of blood insulin using commercially available Eliza kits. Before and following 4 weeks of supplementation and placebo.
Primary Changes in glycated hemoglobin (HbA1c) following 4 weeks of supplementation and placebo. Measurement of HbA1c using commercially available kits. Before and following 4 weeks of supplementation and placebo.
Secondary Changes in body composition following 4 weeks of intervention and placebo. Body fat mass (in kg) and percentage, lean mass (in kg) and percentage Before and following 4 weeks of supplementation and placebo.
Secondary Changes in body mass index following 4 weeks of intervention and placebo. Body mass (in kg) and height (in cm) Before and following 4 weeks of supplementation and placebo.
Secondary Changes in resting heart rate following 4 weeks of intervention and placebo. Resting heart rate (beats per minute) measurement after at least 5 minutes at rest Before and following 4 weeks of supplementation and placebo.
Secondary Changes in blood pressure following 4 weeks of intervention and placebo. Measurement of (systolic and diastolic) blood pressure (in mm Hg) after at least 5 minutes at rest Before and following 4 weeks of supplementation and placebo.
Secondary Changes in waist-to-hip ratio following 4 weeks of intervention and placebo. Measurement of waist and hip circumference to calculate waist-to-hip ratio Before and following 4 weeks of supplementation and placebo.
Secondary Changes in complete blood count following 4 weeks of intervention and placebo. Complete blood count Before, immediately after and 1 hour after each trial of exercise, in both conditions (supplement and placebo)
Secondary Changes in psychometric test following 4 weeks of intervention and placebo. Hospital Anxiety Depression Scale-HADS (Greek version) Before and following 4 weeks of supplementation and placebo.
Secondary Trial of VO2peak estimation. VO2peak (mL/kg body weight/min) estimation with a treadmill protocol. Before intervention.
Secondary Nicotinamide-adenine dinucleotide phosphate (NADPH) Spectrophotometric assay for the determination of NADPH in erythrocytes. Before, immediately after and 1 hour after each trial of exercise, in both conditions (supplement and placebo)
Secondary Glutathione Reductase (GR) Spectrophotometric assay for the determination of GR in erythrocytes. Before, immediately after and 1 hour after each trial of exercise, in both conditions (supplement and placebo)
Secondary Glutathione peroxidase (GPx) Spectrophotometric assay for the determination of GPx in erythrocytes. Before, immediately after and 1 hour after each trial of exercise, in both conditions (supplement and placebo)
Secondary Superoxide dismutases (SOD) Spectrophotometric assay for the determination of SOD in erythrocytes. Before, immediately after and 1 hour after each trial of exercise, in both conditions (supplement and placebo)
Secondary Glucose Tolerance Test (GTT) GTT for the investigation of changes in glucose control. Before intervention (blood samples at 0, 30, 60, 90 and 120 minutes after intake of 75 g glucose).
Secondary G6PD enzyme activity in erythrocytes Quantification of G6PD activity in erythrocytes (units/gram of hemoglobin) of all participants using a commercially available kit. Before intervention. During GTT (blood samples at 0, 30, 60, 90 and 120 minutes after intake of 75 g glucose). Also before, immediately after and 1, 2, 24 hours after each trial of exercise, in both conditions (supplement and placebo).
See also
  Status Clinical Trial Phase
Completed NCT03255187 - Effect of Dietary Supplemental Fish Oil in Alleviating Health Hazards Associated With Air Pollution N/A
Completed NCT04136821 - The Long-term Effects of Oceanix™ on Resistance Training Adaptations N/A
Recruiting NCT03790345 - Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics Phase 2/Phase 3
Completed NCT03358524 - Effects of Vitamin E Supplementation on Free Radicals and Fat Level of Obese Adolescence in Jakarta, Indonesia Phase 4
Recruiting NCT05327348 - Effectiveness of IV Vitamin C in Reducing Oxidative Stress Associated With Free Flap Surgery Phase 3
Completed NCT03288623 - The Effects of Dark Chocolate Implementation in Elite Athletes N/A
Completed NCT04419025 - Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease Phase 2
Completed NCT04597983 - Effect of 8-week Intake of 2S-hesperidin on Performance, Body Composition and Biochemicals Markers in Amateur Cyclists N/A
Not yet recruiting NCT06159543 - The Effects of Fresh Mango Consumption on Cardiometabolic Outcomes in Free-living Individuals With Prediabetes N/A
Enrolling by invitation NCT03030456 - Whole Body Vibrations on Functional Capacity, Muscular Strength, and Biochemical Profile in Elders N/A
Completed NCT02256254 - SIMOX - Induction of Oxidative Stress Phase 2
Not yet recruiting NCT02202239 - Effect of Induction and Maintenance of Anesthesia With Etomidate on Hemodynamics and Oxidative Stress in Diabetic Patients Phase 4
Recruiting NCT02048592 - Impact of Immunonutrition on the Patients With Cystic Fibrosis Phase 4
Completed NCT01942460 - Ferumoxytol for Iron-Deficiency Anemia in Chronic Kidney Disease and Peritoneal Dialysis Patients Phase 4
Completed NCT02463318 - The Effect of Melatonin on Gene Expression and Activity of the Sirt1 and Its Target Genes Catalase and MnSOD in Multiple Sclerosis Patients and Healthy Subjects N/A
Completed NCT01990391 - Brazil Nut Consumption in Microvascular Endothelial Function, Oxidative Stress and Metabolic Abnormalities N/A
Completed NCT02177383 - Action of Essential Fatty Acids on the Expression of Antioxidant Genes and Athletic Performance N/A
Completed NCT00845130 - Quantitative in Vivo Biomarkers of Oxidative Stress in Diabetes N/A
Completed NCT00607893 - Efficacy of Continuous Positive Airway Pressure in Reducing Oxidative Stress in Individuals With Sleep Apnea N/A
Active, not recruiting NCT00247507 - The Effects of Acetylcysteine on Alleviating Damage of Oxidative Stress in Hemodialysis Patients Phase 4